Eli Lilly, a U.S. pharmaceutical giant, has entered into a $2.75 billion agreement with Hong Kong-listed Insilico Medicine to bring AI-developed drugs to the global market [1]. The deal includes an upfront payment of $115 million to Insilico, with the remainder contingent on regulatory and commercial milestones, as well as royalties on future sales [1]. This collaboration builds on a prior AI-based software licensing agreement signed in 2023 between the two companies [1].
Insilico Medicine, which went public in Hong Kong in December, has developed at least 28 drugs using generative AI tools, with nearly half already at a clinical stage, according to its founder and CEO Alex Zhavoronkov [1]. Insilico's shares have risen more than 50% year-to-date, reflecting strong investor confidence in its AI-driven drug discovery approach [1]. Zhavoronkov highlighted Eli Lilly's competitive edge in certain aspects of AI, noting that the U.S. company has integrated biology, chemistry, and automation under one roof [1]. As part of the deal, Insilico will join Lilly's Gateway Labs community for biotech development [1].
Andrew Adams, group vice president of Molecule Discovery at Lilly, stated that the collaboration will allow both companies to explore novel mechanisms and accelerate the identification of promising therapeutic candidates across multiple disease areas. He described Insilico's AI-enabled discovery as a "powerful complement" to Lilly's clinical development capabilities [1].
Eli Lilly CEO David A. Ricks recently attended a high-level forum in Beijing, following the company's announcement of plans to invest $3 billion in China over the next decade. Last year, slightly less than 3% of Lilly's revenue came from China [1]. Insilico develops its AI outside of China, in Canada and the Middle East, but conducts early preclinical drug development in China based on that AI research. Zhavoronkov emphasized that AI can reduce research time and synthesize molecules more quickly than traditional methods [1].
CONCLUSION
The $2.75 billion partnership between Eli Lilly and Insilico Medicine marks a significant step in leveraging AI for drug discovery, with substantial financial commitments and global ambitions. Insilico's strong share performance and the companies' focus on accelerating therapeutic development signal positive market sentiment. The deal is expected to enhance both firms' capabilities and drive innovation in multiple disease areas.